Core Viewpoint - The company has updated its share buyback plan, indicating confidence in its long-term growth and market performance, as the current stock price is perceived to be below its true value [1] Group 1: Share Buyback Plan - The updated share buyback plan allows the company to repurchase up to 25,461,295 shares over a period of 50 trading days starting from November 13, 2025 [1] - The total shares to be repurchased, including those already bought back in 2025, will represent 5% of the total issued shares as of the authorization date [1] Group 2: Management Confidence - The board believes that the share buyback plan reflects the confidence of the directors and senior management in the company's long-term growth and market performance [1] - The board asserts that the buyback plan is in the best interest of the company and its shareholders [1] Group 3: Shareholder Activity - The company has been informed that Yijie Biotechnology Holdings Limited and its concert parties have cumulatively purchased 100,000 shares between November 6 and November 10, 2025 [1] - Following this purchase, the concert group holds a total of 218,048,730 shares, representing approximately 37.92% of the total issued shares (excluding treasury shares) [1] - The board views this increase in shareholding as a sign of confidence from major shareholders regarding the company's prospects and growth potential [1]
科济药业-B(02171.HK)获一名主要股东益杰增持10万股